GRIPP2 reporting checklists : tools to improve reporting of patient and public involvement in research by Staniszewska, Sophie et al.
  
 
 
 
warwick.ac.uk/lib-publications 
 
 
 
 
 
Original citation: 
Staniszewska, Sophie, Brett, J., Simera, I., Seers, Kate, Mockford, Carole, Goodlad, S., Altman, 
D. G., Moher, D., Barber, R., Denegri, S., Entwistle, A., Littlejohns, P., Morris, C., Suleman, R., 
Thomas, V. and Tysall, C.. (2017) GRIPP2 reporting checklists : tools to improve reporting of 
patient and public involvement in research. BMJ, 358 . j3453. 
 
Permanent WRAP URL: 
http://wrap.warwick.ac.uk/91556                   
       
Copyright and reuse: 
The Warwick Research Archive Portal (WRAP) makes this work of researchers of the 
University of Warwick available open access under the following conditions. 
 
This article is made available under the Creative Commons Attribution 4.0 International 
license (CC BY 4.0) and may be reused according to the conditions of the license.  For more 
details see: http://creativecommons.org/licenses/by/4.0/   
 
A note on versions: 
The version presented in WRAP is the published version, or, version of record, and may be 
cited as it appears here. 
 
For more information, please contact the WRAP Team at: wrap@warwick.ac.uk 
 
the bmj | BMJ 2017;358:j3453 | doi: 10.1136/bmj.j3453 1
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GRIPP2 reporting checklists: tools to improve reporting of 
patient and public involvement in research
S Staniszewska,1 J Brett,2 I Simera,3 K Seers,1 C Mockford,4 S Goodlad,5 D G Altman,6 D Moher,7 
R Barber,8 S Denegri,9 A Entwistle,4 P Littlejohns,10 C Morris,11 R Suleman,4 V Thomas,12 C Tysall4
GRIPP2 (short form and long form) is the 
first international guidance for reporting 
of patient and public involvement in 
health and social care research. This 
paper describes the development of the 
GRIPP2 reporting checklists, which aim 
to improve the quality, transparency, 
and consistency of the international 
patient and public involvement (PPI) 
evidence base, to ensure that PPI 
practice is based on the best evidence
ABSTRACT
BACKGROUND
While the patient and public involvement (PPI) 
evidence base has expanded over the past decade, 
the quality of reporting within papers is often 
inconsistent, limiting our understanding of how it 
works, in what context, for whom, and why.
OBJECTIVE
To develop international consensus on the key 
items to report to enhance the quality, transparency, 
and consistency of the PPI evidence base. To 
collaboratively involve patients as research partners 
at all stages in the development of GRIPP2.
METHODS
The EQUATOR method for developing reporting 
guidelines was used. The original GRIPP (Guidance 
for Reporting Involvement of Patients and the Public) 
checklist was revised, based on updated systematic 
review evidence. A three round Delphi survey was 
used to develop consensus on items to be included 
in the guideline. A subsequent face-to-face meeting 
produced agreement on items not reaching consensus 
during the Delphi process.
RESULTS
143 participants agreed to participate in round one, 
with an 86% (123/143) response for round two and 
a 78% (112/143) response for round three. The 
Delphi survey identified the need for long form (LF) 
and short form (SF) versions. GRIPP2-LF includes 
34 items on aims, definitions, concepts and theory, 
methods, stages and nature of involvement, context, 
capture or measurement of impact, outcomes, 
economic assessment, and reflections and is suitable 
for studies where the main focus is PPI. GRIPP2-
SF includes five items on aims, methods, results, 
outcomes, and critical perspective and is suitable for 
studies where PPI is a secondary focus.
CONCLUSIONS
GRIPP2-LF and GRIPP2-SF represent the first 
international evidence based, consensus informed 
guidance for reporting patient and public involvement 
in research. Both versions of GRIPP2 aim to improve 
the quality, transparency, and consistency of the 
international PPI evidence base, to ensure PPI 
practice is based on the best evidence. In order to 
encourage its wide dissemination this article is freely 
accessible on The BMJ and Research Involvement and 
Engagement journal websites.
The EQUATOR network has developed high 
standard reporting guidelines such as the CONSORT 
(Consolidated Standards of Reporting Trials) statement 
and the STROBE (Strengthening the Reporting of 
Observational Studies in Epidemiology) statement 
enhancing the quality of research reporting, but no 
guidance has been developed specifically for the 
reporting of patient and public involvement (PPI). 
This prompted the development of the original 
Guidance for Reporting Involvement of Patients 
and the Public (GRIPP), which tackled inconsistent 
reporting by helping researchers, patients, carers, 
and the public to improve the quality, consistency, 
and transparency of PPI reporting, to strengthen the 
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LAy SummARy
Patient and public involvement in health and social care research is increasingly 
important, helping to ensure that the research focuses on issues relevant 
to patients and the public. A wide variety of research papers with public 
involvement has been published over the past decade, yet many of these papers 
give little information about how members of the public were involved and what 
the result of this involvement was. This means that learning from these studies 
is limited. Working closely with patients and the public, we have developed 
guidance for people writing about public involvement to suggest what details to 
report. We carried out a thorough assessment of studies in this area and used a 
Delphi survey to ask 143 people who are knowledgeable about this topic for their 
opinions about what should be included in the guidance. The Delphi method 
consists of a series of questionnaires over a specific time period to find out 
whether there is agreement among experts about the topic under discussion. We 
found strong agreement on a number of issues to include in the guidance from 
the 112 people who completed three rounds of Delphi questionnaires. We also 
held a one day meeting to find out whether any additional issues for which we 
hadn’t reached agreement should be included in the guidance.
As a result of this three stage project, we developed two versions of the 
guidance, a short version of the guidance (GRIPP2-SF), which can be used 
when reporting public involvement in any study, and a long version (GRIPP2-
LF) to use when the study is mainly about public involvement in research. Our 
aim in developing this guidance is to promote good quality reporting of public 
involvement, to inform good practice and create effective public involvement.
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quality of the international PPI evidence base.1 While 
the original GRIPP checklist represented an important 
starting point in creating high quality PPI reporting, 
its development drew on systematic review evidence, 
without broader input from the international PPI 
research community.2-4 Achieving consensus is now 
acknowledged as a crucial step in producing a reporting 
guideline.5 GRIPP2 tackled this gap by developing 
consensus in the international PPI community.
INVOLVE defines public involvement in research as 
being carried out with or by members of the public 
rather than to, about, or for them. PPI in research 
can improve the relevance and overall quality of 
research, by ensuring that it focuses on the issues of 
importance to patients.1 This includes, for example, 
working with research funders to prioritise research; 
the development of more patient relevant research 
questions, study designs, and outcomes; offering the 
patient perspective as members of a project steering 
group; commenting on and developing research 
materials to improve readability; assisting with 
recruitment to studies; lay write up of the studies; 
and advocacy of study results.2-4 6-9 In the UK, the 
National Institute for Health Research has provided 
vital strategic and infrastructure support to embed 
PPI across publicly funded research, creating a 
context where PPI is seen as a key element in research. 
Internationally PPI is also developing, with similar 
initiatives in Canada, United States, Australia, and 
Europe.10 11 Networks such as the citizen and patient 
involvement group of Health Technology International 
have evolved, enabling international collaboration in 
relation to involvement and engagement.12
While the PPI evidence base has expanded 
significantly over the past decade, the reporting of 
PPI in papers has often been inconsistent and partial, 
with little information about the context, process, 
and impact of public involvement and with limited 
reporting of conceptualisation or theorisation.1-4 
Inadequate reporting can create problems for 
systematic reviews that attempt to synthesise PPI 
evidence.2-4 Appraisal, interpretation, and synthesis of 
results are difficult, aside from the ethical imperatives 
of reporting research in a way that others understand 
and can use.13-16 Inconsistent reporting creates a 
fragmented evidence base making it difficult to draw 
together our collective understanding of what works, 
for whom, why, and in what context. Furthermore, 
researchers, patients, carers, or clinicians cannot learn 
from previous experience, and precious resources 
devoted to involving patients and the public are 
wasted. Omitting descriptions of PPI activities from a 
study can represent a form of misreporting and might 
misrepresent the initial intentions of a study.
This article introduces the two versions of the GRIPP2 
reporting checklist: GRIPP2-LF, a longer checklist for 
studies where PPI forms the primary focus of a study 
(table 1) and GRIPP2-SF, a short checklist for studies 
where PPI is a secondary or tertiary focus (table 2). We 
also describe the development of GRIPP2 and outline 
how it can be used.
GRIPP2 reporting checklist development methods
The study used the EQUATOR method for developing 
reporting guidelines,5 which included: systematic 
review evidence; a three stage Delphi survey including 
key stakeholders in the field of PPI; and a face-to-
face collaborative meeting to develop consensus 
on items outstanding from the Delphi survey. A 
summary of methods is presented, with a companion 
paper reporting the rationale for GRIPP2 and the full 
methods.17 For the purposes of this paper, we have 
therefore reported only a summary of key steps in 
appendix 1.
The systematic reviews that underpinned the 
original GRIPP checklist had already identified the 
need for the guidance.2-4 The PIRICOM systematic 
review, which included the conceptualisation, 
definition, measurement, impact, and outcomes of PPI 
on research, researchers, service users, participants, 
funders, and policy makers, was updated for GRIPP2 
to ensure no additional concepts were omitted from the 
Delphi survey. In addition, searches were conducted to 
identify any other reporting guidelines for PPI.
Three rounds of the Delphi survey were conducted 
to gain consensus (see appendix 2). This included 
143 international participants in round one, with 
an 86% (123/143) response for round two and a 
78% (112/143) response for round three reflecting 
the standard number of participants used in the 
development of previous EQUATOR guidance.5 
Participants of the Delphi survey included researchers, 
funders, patients, carers, editors, and individuals 
from international research agencies from countries 
including Australia, the United States, Canada, and 
Europe. Collectively, participants represented a wide 
range of expertise relevant to the development of 
consensus in PPI reporting.
Participants were asked to rate each item in the 
checklist on a scale of 1-10, with 1 considered 
unimportant and 10 considered very important, and 
medians and interquartile ranges were calculated for 
each item in the Delphi survey. Space next to each 
item was used for free text comments with suggested 
refinements, reiterations, and additional items. If items 
reached a median score of ≥8 in round one and round 
two they were considered to have reached positive 
consensus and included. Items that reached a median 
≤5 in rounds one and two were excluded from the 
checklist. Items that reached a medium score of 6 or 7 in 
one round and a median score of ≥8 in the other round 
were voted on again in round three. Positive consensus 
was gained if the items scored a median score of ≥8 in 
two of the rounds. An important finding from the first 
round was that participants thought GRIPP items were 
most relevant when the main focus of a study was on 
PPI, and many felt there should be a shorter version 
for papers that included some element of PPI. As a 
result participants were asked to identify and score 
“core” items in round two which could be included 
in a shortened version of the guideline, suitable for 
studies that have included PPI as a secondary focus. 
The five core items that comprise the GRIPP2-SF all 
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Table 1 | GRIPP2 long form
Section and topic Item Reported on page No
Section 1: Abstract of paper
 1a: Aim Report the aim of the study
 1b: Methods Describe the methods used by which patients and the public were involved
 1c: Results Report the impacts and outcomes of PPI in the study
 1d:Conclusions Summarise the main conclusions of the study
 1e: Keywords Include PPI, “patient and public involvement,” or alternative terms as keywords
Section 2: Background to paper
 2a: Definition Report the definition of PPI used in the study and how it links to comparable studies
 2b: Theoretical underpinnings Report the theoretical rationale and any theoretical influences relating to PPI in the study
 2c: Concepts and theory development Report any conceptual models or influences used in the study
Section 3: Aims of paper
 3: Aim Report the aim of the study
Section 4: Methods of paper
 4a: Design Provide a clear description of methods by which patients and the public were involved
 4b: People involved Provide a description of patients, carers, and the public involved with the PPI activity in the study
 4c: Stages of involvement Report on how PPI is used at different stages of the study
 4d: Level or nature of involvement Report the level or nature of PPI used at various stages of the study
Section 5: Capture or measurement of PPI impact
 5a: Qualitative evidence of impact If applicable, report the methods used to qualitatively explore the impact of PPI in the study
 5b: Quantitative evidence of impact If applicable, report the methods used to quantitatively measure or assess the impact of PPI
 5c: Robustness of measure If applicable, report the rigour of the method used to capture or measure the impact of PPI
Section 6: Economic assessment
 6: Economic assessment If applicable, report the method used for an economic assessment of PPI
Section 7: Study results
 7a: Outcomes of PPI Report the results of PPI in the study, including both positive and negative outcomes
 7b: Impacts of PPI Report the positive and negative impacts that PPI has had on the research, the individuals involved  
(including patients and researchers), and wider impacts
 7c: Context of PPI Report the influence of any contextual factors that enabled or hindered the process or impact of PPI
 7d: Process of PPI Report the influence of any process factors, that enabled or hindered the impact of PPI
 7ei: Theory development Report any conceptual or theoretical development in PPI that have emerged
 7eii: Theory development Report testing of theoretical models, if any
 7f: Measurement If applicable, report all aspects of instrument development and testing (eg, validity, reliability, feasi-
bility, acceptability, responsiveness, interpretability, appropriateness, precision)
 7g: Economic assessment Report any information on the costs or benefit of PPI
Section 8: Discussion and conclusions
 8a: Outcomes Comment on how PPI influenced the study overall. Describe positive and negative effects
 8b: Impacts Comment on the different impacts of PPI identified in this study and how they contribute to new 
knowledge
 8c: Definition Comment on the definition of PPI used (reported in the Background section) and whether or not you 
would suggest any changes
 8d: Theoretical underpinnings Comment on any way your study adds to the theoretical development of PPI
 8e: Context Comment on how context factors influenced PPI in the study
 8f: Process Comment on how process factors influenced PPI in the study
 8g: Measurement and capture of PPI impact If applicable, comment on how well PPI impact was evaluated or measured in the study
 8h: Economic assessment If applicable, discuss any aspects of the economic cost or benefit of PPI, particularly any suggestions 
for future economic modelling.
 8i: Reflections/critical perspective Comment critically on the study, reflecting on the things that went well and those that did not, so that 
others can learn from this study
PPI=patient and public involvement
gained a median score of 9 in round two. Thus all five 
were included in round three and again gained median 
scores of 9, indicating that consensus was reached on 
the short form version.
Qualitative comments were analysed thematically to 
identify common themes, points of feedback, challenges 
to the items, and queries about wording.18 Qualitative 
comments suggested the need to reword some items 
Table 2 | GRIPP2 short form
Section and topic Item Reported on page No
1: Aim Report the aim of PPI in the study
2: Methods Provide a clear description of the methods used for PPI in the study
3: Study results Outcomes—Report the results of PPI in the study, including both 
positive and negative outcomes
4: Discussion and conclusions Outcomes—Comment on the extent to which PPI influenced the study 
overall. Describe positive and negative effects
5: Reflections/critical perspective Comment critically on the study, reflecting on the things that went well 
and those that did not, so others can learn from this experience
PPI=patient and public involvement
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to simplify them and ensure clarity of meaning. Two 
sections from the original GRIPP checklist, section 5, 
which focused on measurement, and section 6, which 
was focused on capture of impact, were combined as it 
was recognised that they were conceptually overlapping. 
The original section 8 was deleted as participants 
thought it duplicated existing items.
Appendices 3 and 4 report the results of the Delphi 
survey. Following the Delphi survey, a collaborative 
consensus meeting was held with 25 key experts with 
knowledge, experience, or both, of PPI, including 
patient partners and carers (n=8), researchers (n=9), 
clinicians (n=6), and healthcare journal editors (n=2). 
The aim of this meeting was to finalise consensus 
on the seven items on the threshold of consensus 
following the Delphi survey (appendix 2) and ensure 
clarity of the items.
Patient partners were collaboratively involved at key 
stages of the study. Three patient partners were recruited 
to the research team and were involved in refining the 
focus of the research questions, in development of 
the search strategy and interpretation of results of the 
systematic review, in discussions identifying the need 
for development of guidelines, and in selecting the 
items for the original GRIPP checklist. Furthermore, 
the patient partners assisted in developing the 
electronic survey for the first phase of the Delphi 
survey consensus process and were instrumental in 
assisting in recruitment to the Delphi study and in 
collation of comments from each Delphi survey round, 
and contributed to adapting items for GRIPP2. The 
consensus meeting involved eight patient partners in 
total, and the three patient partners recruited to the 
research team were involved in the write-up of the study 
and are coauthors in papers. More detailed information 
of their contribution to the development of GRIPP 
is described using GRIPP2-SF in table 3 and used to 
populate the BMJ PPI guidance in box 1.
Scope and illustration of use
GRIPP2-LF (table 1) and GRIPP2-SF (table 2) are 
the first international, evidence based, community 
consensus informed guidelines for the reporting of PPI 
in research. The checklists provide key PPI concepts 
Table 3 | PPI in the development of GRIPP2 using GRIPP 2-SF*
Section and topic Item
1: Aim 
Report the aim of the study
To develop international consensus on the key items to report to enhance the quality, transparency, and consistency of the PPI evidence 
base. To collaboratively involve patients as research partners at all stages in the development of GRIPP2
2: Methods 
Provide a clear description of the 
methods used for PPI in the study
Three patient partners were recruited to the research team to assist at all stages of the development of and consensus process for the 
GRIPP2 guidelines. They were involved in refining the focus of the research questions, in developing the search strategy, in interpreting 
results, in discussions identifying the need for development of guidelines, and in selecting the items for the original GRIPP checklist. 
The patient partners helped recruit participants (n=60/143) to the Delphi survey through snowballing techniques. They helped pilot 
the electronic survey for the first phase of the Delphi survey consensus process and helped other patient reps with technical aspects of 
completing the online survey, hence improving the response rate in each round of the Delphi. They also worked with the researchers to 
collate comments from each Delphi survey round, to adapt items, and to feed back to the participants for the next Delphi survey round. 
They checked comprehension of changed items and comments from the lay perspective. The patient partners took part in the consensus 
workshop, alongside five other patients (n=8/25 in total) to agree consensus on items not reaching consensus and to adapt wording 
where items were not clear. The patient partners contributed to edits of the paper and are coauthors.
3: Results 
Outcomes—Report the results of PPI 
in the study, including both positive 
and negative outcomes
PPI contributed to the study in several ways, including: 
•  Collating initial evidence
•  Identifying items for the GRIPP checklist
•   Considering the evidence and their wider experience—the patients highlighted the importance of including items referring to the 
context and processes of PPI, suggesting that this affected the impact that PPI had on research
•   The patient partners, along with other patient organisations and charities, recruited nearly half of all participants for the Delphi survey
•   The patient partners helped other patients with the technical aspects of completing the online survey, improving the response rate in 
each Delphi survey round.
•   The patient partners checked the comprehension of the changed items and comments from the lay perspective between rounds and 
were integral to helping the researchers keep to the scheduled time of the Delphi survey
•   Throughout the write-up phase for both the results paper and the methods paper the patient partners contributed to the lay sections 
and contributed to edits of the paper
4: Discussion 
Outcomes—Comment on the extent 
to which PPI influenced the study 
overall. Describe positive and 
negative effects
Patient and public involvement in this study was very effective and influenced important aspects of the study, based on the impacts in 
section 3. This might have been related to several factors. Firstly the patient partners had received training around research methods in 
previous studies, and were actively involved in a patient and public involvement group attached to the University of Warwick. In addi-
tion, the researchers were experienced at involving patient partners in their research. 
The right processes were in place, as the patient partners were involved from the beginning of the study allowing them to help shape 
the study from the start allowing them to contribute fully to the study. Having the right context, with a collaborative research team, 
funding to finance their time, and a supportive attitude of their involvement from EQUATOR and other collaborators, also assisted in the 
positive impact that PPI had on this study. Pre-existing relationships with patient partners and patients who attended the collaborative 
consensus event provided a vital context for embedded PPI. 
However, there were limitations. The methods used to gain consensus had been developed and tested for reliability and validity 
by EQUATOR in the development of previous guidelines, which limited the possible input from the patient partners in identifying or 
developing methods to gain consensus on GRIPP2. Furthermore, the time for feedback between Delphi survey rounds was short, and 
organising times where both researchers and patient partners could meet was difficult. In similar future studies, scheduling of these 
meetings in advance of the Delphi survey might overcome this limitation.
5: Reflections 
Critical perspective—Comment 
critically on the study, reflecting on 
the things that went well and those 
that did not, so others can learn 
from this experience
The PPI in the study was embedded as far as possible into the methods for developing consensus. While not a formal part of EQUATOR 
methodology, the aim of active collaboration in an attempt to co-produce knowledge worked well. The key challenge was the timescales 
required to ensure the Delphi survey was completed with appropriate intervals. If this was repeated, these time scales would require 
extension. We are aware that this process might have limited the extent to which patient partners were able to identify concepts of 
importance that sit outside of the traditional research paradigm and so may require further development in the future.
*An example of using the long form can be obtained from the authors
ReseaRch Methods and RepoRting
the bmj | BMJ 2017;358:j3453 | doi: 10.1136/bmj.j3453 5
that authors should report in papers, to enhance the 
overall quality and transparency of the PPI evidence 
base. GRIPP2-LF and GRIPP2-SF ultimately aspire to 
guide PPI reporting in different types of studies, from 
reporting on PPI in trials (GRIPP2-SF) to reporting of 
PPI focused studies (GRIPP2-LF). Researchers can 
use the reporting guideline prospectively to plan PPI 
in studies and retrospectively as a quality assurance 
step in the writing up of PPI in publications and 
reports. Health and social care research funders and 
research institutions could promote adherence to the 
GRIPP2 reporting checklist as a means to optimise 
the creation of transparent, consistent, and high 
quality PPI evidence. Journal editors could use GRIPP2 
reporting checklists to set their reporting expectations 
for submitted manuscripts. Higher quality reporting 
will gradually lead to the development of a stronger 
PPI evidence base that will facilitate more effective 
synthesis of PPI studies.
GRIPP2 can be used in different ways within a 
paper. For GRIPP 2-LF the entire paper can be shaped 
by the guidance, with researchers selecting the items 
of relevance. With GRIPP2-SF researchers could 
present all the information in the body of the paper 
under the relevant reporting titles or in a separate box. 
Table 3 provides an illustration of GRIPP2 –SF using 
this study as an example. This table is an illustration 
of the potential of GRIPP2 reporting. It is purposefully 
long to demonstrate the type of information it could 
include. A more specific, shorter form of reporting 
would also be acceptable, as long as it contained the 
key information.
Availability
GRIPP2-SF and GRIPP2- LF are available on the 
EQUATOR webpage (www.equator-network.org/), or 
at  http://www2.warwick.ac.uk/fac/med/research/
hscience/wrn/research/themea.
Discussion and limitations
GRIPP2-LF and GRIPP2-SF are the first international, 
evidence based, community consensus informed 
guidelines for the reporting of patient and public 
involvement in research. Although consensus was 
achieved in the development of GRIPP2, further 
refinements are expected over time as the evidence 
base underpinning PPI evolves, reflecting the iterative 
EQUATOR method of guideline development. In 
addition, it has not yet been possible to conduct any 
usability testing to understand how GRIPP2 works 
in practice with different types of study designs. The 
final consensus meeting did not include international 
experts because of a restricted budget, which might 
have limited the discussion from an international 
perspective. Thus, the next phase of development 
for GRIPP2-LF and GRIPP2-SF should include wider 
international application and piloting to test conceptual 
equivalence in different country contexts. Feedback 
from researchers using GRIPP2 will help refine it. We 
have created a comment box on the Warwick Medical 
School website to facilitate this http://www2.warwick.
ac.uk/fac/med/research/hscience/
Guidelines such as the CONSORT statement for 
randomised controlled trials (RCTs) are regularly 
updated to reflect changes in health research more 
widely.19 Such evolution is particularly important 
for GRIPP2 because PPI is at a pre-paradigm stage in 
its development and recognition, reflecting Kuhn’s 
conceptualisation of how science changes over time 
with significant paradigm shifts that generate new 
ways of thinking.20
While GRIPP2-LF and GRIPP2-SF aim to guide 
consistent reporting, it is not possible to be prescriptive 
about the exact content of each item, as the current 
evidence base is not advanced enough to make this 
possible.2-4 21 Authors should carefully consider the 
relevance of each GRIPP2 item but recognise that it is 
sometimes not necessary, or even possible, to include 
each item in a particular manuscript. With future 
development of the evidence base, it will be possible to 
refine GRIPP items, and some may become mandatory.
The success of the PPI in this study may relate 
to several factors. Firstly, the patient partners had 
received training around research methods in previous 
studies and were actively involved in a patient and 
public involvement group attached to the University of 
Warwick Medical School. Furthermore, the researchers 
were experienced at involving patient partners in their 
research.22 Finally, good relationships and ways of 
working were established, which are known as key 
factors for facilitating high quality PPI.4 21
We recognise that GRIPP2 was developed with 
experts familiar with PPI and that there are still 
significant challenges in academic culture in enacting 
Box 1: Patient and public involvement in GRIPP2 according to BMJ guidance
How was the development of the research question and outcome measures informed 
by patients’ priorities, experience, and preferences?
Patients were involved in the original systemic review that underpinned GRIPP and 
actively contributed to identifying the issue of inconsistent reporting, the need for 
guidance, and the research question.
How did you involve patients in the design of this study?
Patients were involved as research partners in all aspects of the study including 
identifying the original research question, identifying the need for the original 
systematic review, and identifying the need for consensus.
Were patients involved in the recruitment to and conduct of the study?
The patient partners, along with other patient organisations and charities, recruited 
nearly half of all participants for the Delphi survey. They helped pilot the electronic 
survey for the first phase of the Delphi survey consensus process and helped other 
patient reps with technical aspects of completing the online survey, hence improving 
the response rate in each round of the Delphi. They also worked with the researchers 
to collate comments from each Delphi survey round, to adapt items, and to feed back 
to the participants for the next Delphi survey round. They checked comprehension of 
changed items and comments from the lay perspective. The patient partners took 
part in the consensus workshop, alongside five other patients (n=8/25 in total) to 
agree consensus on items not reaching consensus and to adapt wording where 
items were not clear. The patient partners contributed to edits of the paper and are 
coauthors.
How will the results be disseminated to study participants?
GRIPP2 will be disseminated to all study participants via email. The authors will 
disseminate via conference presentations. Funding bodies and other journal editors 
internationally will be encouraged to use GRIPP2.
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the behaviour changes that public involvement 
requires. PPI needs to become embedded practice 
within research rather than an option, and both 
researchers and patients need to recognise their own 
training and development needs, drawing on the 
evidence base to guide effective practice.
A further limitation is that GRIPP2-LF and GRIPP2-
SF are conceptualised within the culture and language 
of research. Bearing in mind that the ultimate intention 
of high quality reporting in PPI is to develop best 
practice, there is a need to develop a patient or service 
user version of GRIPP2 to ensure comprehensibility 
and usefulness and to ensure that patient important 
concepts indicative of high quality research are 
included, although these are yet to be identified. 
This would reflect important changes in academic 
publishing, where patients are regularly writing and 
peer reviewing academic papers and require ways of 
understanding reporting quality.22 Used alongside 
other EQUATOR guidance, the intention is to guide the 
development of a transparent, consistent, and high 
quality PPI evidence base. More effective synthesis of 
the PPI evidence base will help to identify best practice, 
avoid poor practice, and contribute to research that is 
acceptable, relevant, appropriate, and high quality 
and that has the potential to generate benefit for all.
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